别嘌醇治疗获得性反应性穿通性胶原病。

Allopurinol in the treatment of acquired reactive perforating collagenosis.

作者信息

Tilz Hemma, Becker Jürgen Christian, Legat Franz, Schettini Antonio Pedro Mendes, Inzinger Martin, Massone Cesare

机构信息

Department of Dermatology, Division of General Dermatology, Medical University of Graz, Graz, Austria.

出版信息

An Bras Dermatol. 2013 Jan-Feb;88(1):94-7. doi: 10.1590/s0365-05962013000100012.

DOI:10.1590/s0365-05962013000100012

PMID:23539010

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3699945/

Abstract

Acquired reactive perforating collagenosis is a perforating dermatosis usually associated with different systemic diseases, mainly diabetes mellitus and/or chronic renal insufficiency. Different therapies have been tried but treatment is not standardized yet and remains a challenge. In the last few years, allopurinol has been reported as a good therapeutic option for acquired reactive perforating collagenosis. We describe the case of a 73-year-old man affected by acquired reactive perforating collagenosis associated with diabetes type 1 and chronic renal failure with secondary hyperparathyroidism. The patient was successfully treated with allopurinol 100mg once/day p.o..

摘要

获得性反应性穿通性胶原病是一种穿通性皮肤病，通常与不同的全身性疾病相关，主要是糖尿病和/或慢性肾功能不全。人们尝试了不同的治疗方法，但治疗尚未标准化，仍然是一个挑战。在过去几年中，已有报道称别嘌醇是治疗获得性反应性穿通性胶原病的一种良好治疗选择。我们描述了一名73岁男性的病例，他患有与1型糖尿病和继发性甲状旁腺功能亢进相关的慢性肾衰竭的获得性反应性穿通性胶原病。该患者通过口服别嘌醇100mg每日一次成功治愈。